NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Daily Buy Back of equity shares
Extinguishment of 87050 Equity Shares bought under Buy-back06-04-2023
NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Daily Buy Back of equity shares
Extinguishment of 87050 Equity Shares bought under Buy-backNATCO PHARMA LTD. - 524816 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Details of Loss of Share CertificateNATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Daily Buy Back of equity shares
Daily report pursuant to Regulation 18(i) of the Buyback Regulations regarding the equity shares bought-back on April 06, 2023. Total no. of equity shares bought back are 0NATCO PHARMA LTD. - 524816 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Compliance Certificate under Reg 74(5) of SEBI (DP) Regulations for the quarter ended 31st March 2023Natco, MacLeods to launch their versions of Bedaquiline
Bedaquiline is J&J's breakthrough TB drug; patent to expire in JulyNATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Daily Buy Back of equity shares
Daily report pursuant to Regulation 18(i) of the Buyback Regulations regarding the equity shares bought-back on April 03, 2023. Total no. of equity shares bought back are 4300NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Daily Buy Back of equity shares
Daily report pursuant to Regulation 18(i) of the Buyback Regulations regarding the equity shares bought-back on March 31, 2023. Total no. of equity shares bought back are 0NATCO PHARMA LTD. - 524816 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Details of Loss of Share CertificateNATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Daily Buy Back of equity shares
Daily report pursuant to regulation 18(i) of the Buyback Regulations regarding the Equity Shares bought-back on March 28, 2023 are 4450